|
|
08/11/2006
Swiss Medica Launches O24 Sampling Campaign With Golf Magazine and At Major Golf Courses
Thursday August 24, 8:00 am ET
TORONTO, Aug. 24, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTC BB:SWME.OB - News) announced today
that Golf Magazine has distributed over 400,000 O24 Pain Neutralizer information postcards with an attached
free sample towelette as an insert to their 55+ year old magazine subscribers in the United States. The sample
towelettes were included in the September 2006 issue of Golf Magazine. Golf Magazine is the world's most widely
read golf publication, and is read by millions of golfers each month.
Grant Johnson, President and COO of Swiss Medica stated that ``While the magazine has only been in
circulation for less than a week, we are already seeing a dramatic pick-up on our http://www.024zone.com
website and 1-877 toll-free customer care line regarding where they can buy O24.''
O24 is also being sampled to over 100,000 golfers this summer at golf tournaments in Canada and in
clubhouses including Angus Glen Golf Club (north of Toronto), the home to the 2007 Canadian Open PGA golf
tournament.
``O24 has received an enthusiastic response from golfers who have found its strong and quick pain relief to be
very effective to deal with pain and stiffness, both on and off on the Golf Course,'' stated Kevin Thistle, Vice
President/General Manager of Angus Glen Golf Club.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-
tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through
innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in
the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our
websites at http://www.swissmedica.com, http://www.O24zone.com and http://www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds U.S. Patent No. 6,444,238B1. The
O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by
healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-
the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can
also visit http://www.O24zone.com for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (U.S. Patent No. 6,444,238B1)
over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded
O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain
associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 percent of the
patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 percent who
used the placebo. Customers can also visit http://www.O24zone.com, for ordering details and store locators for
the nearest retailer.
Swiss Medica also distributes PMS Escape(r) which holds U.S. Patent Nos. 5760014 and 5612320. PMS Escape
(r) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes
in mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the ``Safe Harbor'' provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss
Medica's products in Canada, the United States and other countries, risks related to international sales and
purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products,
increased levels of competition, dependence on intellectual property rights and other risks detailed from time to
time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and
other regulatory authorities.
|
|
